Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.80 USD
Change Today +0.02 / 1.12%
Volume 20.4K
ECTE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

echo therapeutics inc (ECTE) Snapshot

Open
$1.85
Previous Close
$1.78
Day High
$1.88
Day Low
$1.80
52 Week High
02/19/15 - $3.00
52 Week Low
09/24/14 - $0.39
Market Cap
20.0M
Average Volume 10 Days
16.8K
EPS TTM
$-1.68
Shares Outstanding
11.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ECHO THERAPEUTICS INC (ECTE)

Related News

No related news articles were found.

echo therapeutics inc (ECTE) Related Businessweek News

No Related Businessweek News Found

echo therapeutics inc (ECTE) Details

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer market and diabetes outpatient market. It is developing Symphony continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system for use in hospital critical care units. The company is also developing Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses; and methotrexate-AzoneTS, a AzoneTS reformulation drug that has completed Phase II clinical studies for the treatment of early-stage mycoses fungoides, as well as developing for methotrexate-AzoneTS for the treatment of psoriasis. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

7 Employees
Last Reported Date: 04/15/15
Founded in 1989

echo therapeutics inc (ECTE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $12.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $8.0K
Compensation as of Fiscal Year 2014.

echo therapeutics inc (ECTE) Key Developments

Worldwide Business with kathy ireland® Selects Echo Therapeutics, Inc. for Wearable Technology Feature

Echo Therapeutics, Inc. announced that it was selected to be included in a wearable fitness tracking and monitoring technology segment on Worldwide Business with kathy ireland®, a weekly business program. The segment, which will appear on Fox Business Network (as pd. prog) in the United States and Bloomberg International (as pd. prog.) globally, will be hosted by Ireland and will illustrate the features and benefits of Echo's continuous glucose monitoring technology in the wearable health market.

Echo Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Echo Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. Echo's net loss for the first quarter of 2015 was $8.3 million, or $0.72 per basic and diluted share, compared to $2.8 million, or $0.23 per basic and diluted share, for the same period in 2014. The $5.5 million increase in net loss was a result of a non-cash financing charge in the first quarter for the approximate same amount. Operating loss for the first quarter of 2015 was $2.5 million compared to $2.7 million for the first quarter of 2014.

Echo Therapeutics, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 11:00 AM

Echo Therapeutics, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 11:00 AM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States. Speakers: Scott W. Hollander, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECTE:US $1.80 USD +0.02

ECTE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.41 USD -0.11
Bayer AG €126.31 EUR -0.59
Johnson & Johnson $98.44 USD -0.03
Roche Holding AG SFr.265.10 CHF -1.30
View Industry Companies
 

Industry Analysis

ECTE

Industry Average

Valuation ECTE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 513.8x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 475.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECHO THERAPEUTICS INC, please visit www.echotx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.